 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
59 News |  |
- Dextenza (dexamethasone punctal plug) / Ocular Therap
Trial completion: Dex-AC: DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (clinicaltrials.gov) - Apr 13, 2022
P4, N=31, Completed, Sponsor: Clinical Research Center of Florida
Not yet recruiting --> Completed
- | Eysuvis (loteprednol etabonate nano-suspension 0.25%) / Kala Pharma
Journal: Loteprednol 0.25% (Eysuvis) for dry eye disease. (Pubmed Central) - May 26, 2021
Not yet recruiting --> Completed No abstract available
- | Dextenza (dexamethasone punctal plug) / Ocular Therap
New P4 trial: Dex-AC: DEXTENZA Therapy for Treatment of Allergic Conjunctivitis (clinicaltrials.gov) - Jan 13, 2021
P4, N=30, Not yet recruiting, Sponsor: Clinical Research Center of Florida
- || Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
I #vote with you @biljana_parapid : Team #RadialRex (Twitter) - Oct 30, 2020
- || Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
Thai central bank says ready to curb resilient baht if needed https://t.co/TMkmalrExV (Twitter) - Jan 14, 2020
- | Xyrem (sodium oxybate) / Jazz, UCB, Bausch Health
Clinical, Journal: Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. (Pubmed Central) - Oct 8, 2019
However, a pharmacovigilance database of more than 260 000 alcohol-dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well-tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol-dependent patients with VH DRL.
- | Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
New P4 trial: Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium (clinicaltrials.gov) - Aug 29, 2019
P4, N=108, Completed, Sponsor: Wannisa Suphachearabhan
- | Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
Preclinical, Journal: Pathogenesis of myeloproliferative neoplasms: insights from mouse models (Pubmed Central) - Jul 6, 2019
One of the main molecular features of myeloproliferative neoplasms (MPNs) is the high frequency of JAK2V617F or CALRexon 9 mutations...The mutation landscape of hematological tumors has already been clarified using next-generation sequencing technology, and future research on the importance of the functional analysis of mutant genes in vivo should be emphasized. Thus, it is necessary to promote rapid genetic modification techniques such as genome editing.
- Bepreve (bepotastine besilate ophthalmic solution) / Bausch Health, Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
Enrollment change: Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis (clinicaltrials.gov) - Jan 17, 2013
P4, N=23, Completed, Sponsor: Southern California College of Optometry
Thus, it is necessary to promote rapid genetic modification techniques such as genome editing. N=50 --> 23
- Bepreve (bepotastine besilate ophthalmic solution) / Bausch Health, Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
Trial completion: Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis (clinicaltrials.gov) - Jan 17, 2013
P4, N=23, Completed, Sponsor: Southern California College of Optometry
N=50 --> 23 Recruiting --> Completed
- Bepreve (bepotastine besilate ophthalmic solution) / Bausch Health, Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
New P4 trial: Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis (clinicaltrials.gov) - Sep 27, 2011
P4, N=23, Completed, Sponsor: Southern California College of Optometry
- |||||||||| Alrex (loteprednol etabonate opthalmic suspension 0.2%) / Bausch Health
New P3 trial: Alrex (clinicaltrials.gov) - Sep 13, 2011
P3, N=300, Completed, Sponsor: Bausch & Lomb Incorporated